The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Or we are snapped up by one of the big boys , Nasdaq is the key to huge amounts of investment .
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=021-388278&owner=include&count=40
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=021-388278&owner=include&count=40
Reading this is making me feel better .
Lost £10,000 a piece on XEL - oil ‘ explorer’ and Langbar - don’t ask !
Currently up £35,000 with Argo - don’t tell the Mrs .
Big thanks to whoever tipped Argo on the 4d chat in December I owe you one . If your looking for another gem have a look at 4d pharma (DDDD) confirmed listing on NASDAQ on 14 March with another brilliant CEO just like PW . Best of all , one day Rodney ....
Useless , mine haven’t appeared yet
Anyone’s share allocation arrived in their ii account yet ? !
I haven’t received mine either !
Coming soon , GLA.
From the 22nd Oct 2020 RNS
A Circular containing further information about the Merger and 4D General Meeting, together with the associated form of proxy to vote at the 4D General Meeting, will be posted to 4D Shareholders following declaration of effectiveness by the SEC of the Form F-4 to be filed by 4D. The 4D General Meeting and the Longevity Meeting are expected to be held as soon as practicable thereafter.
4D expects to publish and file with the SEC a Registration Statement on Form F-4, which will include a proxy statement of Longevity that also constitutes a prospectus of 4D under SEC rules.
Longevity intends to hold a shareholder meeting on or around 20 November 2020 in order to extend its Business Combination Deadline to 29 May 2021, thereby allowing sufficient time for all of the Conditions to be satisfied and for the Transaction to complete. 4D has received an irrevocable undertaking from Whale to vote in favour of the resolutions to effect the Transaction to be proposed at the general meeting of Longevity Shareholders in respect of holdings totalling, in aggregate, 1,250,000 Longevity Shares, representing 48 per cent. of Longevity 's outstanding shares of common stock.
The Transaction is currently expected to become effective in early 2021, subject to the approval of 4D Shareholders, Longevity Shareholders and the SEC review process.
Admission to NASDAQ
4D intends to apply to list its 4D ADSs on NASDAQ, to be effective at Completion.
ReplyRecommendReport Post
From the 22nd Oct 2020 RNS
A Circular containing further information about the Merger and 4D General Meeting, together with the associated form of proxy to vote at the 4D General Meeting, will be posted to 4D Shareholders following declaration of effectiveness by the SEC of the Form F-4 to be filed by 4D. The 4D General Meeting and the Longevity Meeting are expected to be held as soon as practicable thereafter.
4D expects to publish and file with the SEC a Registration Statement on Form F-4, which will include a proxy statement of Longevity that also constitutes a prospectus of 4D under SEC rules.
Longevity intends to hold a shareholder meeting on or around 20 November 2020 in order to extend its Business Combination Deadline to 29 May 2021, thereby allowing sufficient time for all of the Conditions to be satisfied and for the Transaction to complete. 4D has received an irrevocable undertaking from Whale to vote in favour of the resolutions to effect the Transaction to be proposed at the general meeting of Longevity Shareholders in respect of holdings totalling, in aggregate, 1,250,000 Longevity Shares, representing 48 per cent. of Longevity 's outstanding shares of common stock.
The Transaction is currently expected to become effective in early 2021, subject to the approval of 4D Shareholders, Longevity Shareholders and the SEC review process.
Admission to NASDAQ
4D intends to apply to list its 4D ADSs on NASDAQ, to be effective at Completion.